Avita Medical Inc. (NASDAQ:RCEL) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Avita Medical Inc. (NASDAQ:RCEL) has received a consensus recommendation of "Hold" from analysts, with price targets ranging from $3.00 to $14.00.
• The company reported a loss of ($0.38) earnings per share, missing expectations, and had revenues of $18.42 million for the last quarter.
• Insider buying activity increased as Director Robert McNamara purchased 10,000 shares, indicating confidence in the company's future despite recent performance challenges.

Shares of Avita Medical Inc. (NASDAQ:RCEL - Get Free Report) have received an average recommendation of "Hold" from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.40.

RCEL has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Avita Medical from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Lake Street Capital cut their price target on shares of Avita Medical from $14.00 to $8.00 and set a "buy" rating on the stock in a report on Monday, August 11th. D. Boral Capital cut their price target on shares of Avita Medical from $19.00 to $18.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Finally, BTIG Research lowered shares of Avita Medical from a "neutral" rating to a "sell" rating and set a $3.00 price target on the stock. in a report on Friday, August 8th.

Avita Medical Price Performance

NASDAQ:RCEL opened at $4.29 on Wednesday. The firm has a market cap of $114.20 million, a price-to-earnings ratio of -2.18 and a beta of 1.58. The company has a current ratio of 0.58, a quick ratio of 0.46 and a debt-to-equity ratio of 9.39. The company's 50-day moving average is $5.25 and its two-hundred day moving average is $7.03. Avita Medical has a 12-month low of $3.60 and a 12-month high of $14.16.

Avita Medical (NASDAQ:RCEL - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.12). The firm had revenue of $18.42 million during the quarter, compared to analysts' expectations of $34.27 million. Avita Medical had a negative net margin of 68.87% and a negative return on equity of 632.62%. Avita Medical has set its FY 2025 guidance at EPS. Research analysts expect that Avita Medical will post -0.95 EPS for the current year.

Insider Buying and Selling

In other Avita Medical news, Director Robert Mcnamara purchased 10,000 shares of the business's stock in a transaction that occurred on Thursday, August 28th. The shares were purchased at an average price of $4.50 per share, for a total transaction of $45,000.00. Following the completion of the acquisition, the director owned 86,771 shares of the company's stock, valued at approximately $390,469.50. This represents a 13.03% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have purchased a total of 24,000 shares of company stock valued at $113,660 in the last 90 days. Company insiders own 2.80% of the company's stock.

Institutional Trading of Avita Medical

Hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in shares of Avita Medical during the fourth quarter valued at approximately $38,000. CWM LLC grew its position in shares of Avita Medical by 1,099.5% during the first quarter. CWM LLC now owns 4,918 shares of the company's stock worth $40,000 after buying an additional 4,508 shares in the last quarter. GAMMA Investing LLC grew its position in shares of Avita Medical by 688.9% during the first quarter. GAMMA Investing LLC now owns 6,374 shares of the company's stock worth $52,000 after buying an additional 5,566 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Avita Medical during the first quarter worth approximately $53,000. Finally, The Manufacturers Life Insurance Company acquired a new position in Avita Medical in the second quarter worth $58,000. Hedge funds and other institutional investors own 27.66% of the company's stock.

Avita Medical Company Profile

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.